TBPH

Company Overview — What Does Theravance Biopharma, Inc. Do?

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. Theravance Biopharma, Inc. (TBPH) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Rick E. Winningham and employs approximately 110 people. With a market capitalization of $816M, TBPH is one of the notable companies in the Healthcare sector.

Theravance Biopharma, Inc. (TBPH) Stock Rating — Reduce (April 2026)

As of April 2026, Theravance Biopharma, Inc. receives a Reduce rating with a composite score of 44.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TBPH ranks #2,889 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Theravance Biopharma, Inc. ranks #405 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TBPH Stock Price and 52-Week Range

Theravance Biopharma, Inc. (TBPH) currently trades at $16.35. The stock lost $0.20 (1.2%) in the most recent trading session. The 52-week high for TBPH is $21.03, which means the stock is currently trading -22.3% from its annual peak. The 52-week low is $7.90, putting the stock 107.0% above its annual trough. Recent trading volume was 362K shares, suggesting relatively thin trading activity.

Is TBPH Overvalued or Undervalued? — Valuation Analysis

Theravance Biopharma, Inc. (TBPH) carries a value factor score of 44/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 26.50x, compared to the Healthcare sector average of 23.63x — a premium of 12%. The price-to-book ratio stands at 2.87x, versus the sector average of 2.75x. The price-to-sales ratio is 10.87x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TBPH trades at 19.80x EV/EBITDA, versus 6.34x for the sector.

Overall, TBPH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Theravance Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

Theravance Biopharma, Inc. (TBPH) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 10.8%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 6.6% versus the sector average of -33.1%.

On a margin basis, Theravance Biopharma, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -50.2% (sector: -66.1%). Net profit margin stands at 16.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 40.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TBPH Debt, Balance Sheet, and Financial Health

Theravance Biopharma, Inc. has a debt-to-equity ratio of 64.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 10.93x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $175M.

TBPH has a beta of 0.58, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Theravance Biopharma, Inc. is 58/100, reflecting average volatility within the normal range for its sector.

Theravance Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Theravance Biopharma, Inc. reported revenue of $78M and earnings per share (EPS) of $2.10. Net income for the quarter was $32M. Gross margin was 100.0%. Operating income came in at $-34M.

In FY 2025, Theravance Biopharma, Inc. reported revenue of $107M and earnings per share (EPS) of $2.10. Net income for the quarter was $106M. Revenue grew 66.9% year-over-year compared to FY 2024. Operating income came in at $-4M.

In Q3 2025, Theravance Biopharma, Inc. reported revenue of $20M and earnings per share (EPS) of $0.07. Net income for the quarter was $4M. Revenue grew 18.5% year-over-year compared to Q3 2024. Operating income came in at $-6M.

In Q2 2025, Theravance Biopharma, Inc. reported revenue of $26M and earnings per share (EPS) of $1.09. Net income for the quarter was $55M. Gross margin was 100.0%. Revenue grew 83.7% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Theravance Biopharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $14M to $78M. Investors analyzing TBPH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TBPH Dividend Yield and Income Analysis

Theravance Biopharma, Inc. (TBPH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TBPH Momentum and Technical Analysis Profile

Theravance Biopharma, Inc. (TBPH) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

TBPH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Theravance Biopharma, Inc. (TBPH) ranks #405 out of 838 stocks based on the Blank Capital composite score. This places TBPH in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TBPH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TBPH vs S&P 500 (SPY) comparison to assess how Theravance Biopharma, Inc. stacks up against the broader market across all factor dimensions.

TBPH Next Earnings Date

No upcoming earnings date has been announced for Theravance Biopharma, Inc. (TBPH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TBPH? — Investment Thesis Summary

The quantitative profile for Theravance Biopharma, Inc. suggests caution. The quality score of 27/100 flags below-average profitability. Price momentum is positive at 60/100, suggesting the trend favors buyers.

In summary, Theravance Biopharma, Inc. (TBPH) earns a Reduce rating with a composite score of 44.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TBPH stock.

Related Resources for TBPH Investors

Explore more research and tools: TBPH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TBPH head-to-head with peers: TBPH vs AZN, TBPH vs SLGL, TBPH vs VMD.